Replies to post #47 on Replimune (REPL)

[jondoeuk]

Why the steep drop today?

I haven't been able to find out why.

I hope they plan on releasing something very quick

They will be presenting some data at AACR, but ASCO will be the main event, due to additional data from the RP2 (+/- Opdivo) trial. Last year the data on just nine patients at SITC sent the stock up by around $20-30 (from memory).